Even With CKD, Patiromer Helped Heart Failure Patients Keep Hyperkalemia at Bay
Regardless of chronic kidney disease (CKD) stage, the potassium-binding agent patiromer (Veltassa) improved serum potassium levels in patients with heart failure, according to a prespecified CKD subanalysis from the DIAMOND trial. In a subgroup of patients with heart failure with reduced ejection fraction plus CKD, and hyperkalemia due to renin-angiotensin-aldosterone system inhibitors (RAASi), patiromer significantly […]
Patiromer Limits Impact of RAAS Inhibitor-Related Hyperkalemia in HF
WASHINGTON — Use of the potassium-binding agent patiromer (Veltassa) allowed more heart failure patients at risk for hyperkalemia to remain on optimal therapy with renin-angiotensin-aldosterone system inhibitors (RAAS), including mineralocorticoids, the randomized DIAMOND trial showed. For the study’s revised primary endpoint, patiromer led to a significant reduction in potassium levels by study end versus placebo […]